Poulam Patel

Contact

• workRoom Clinical Oncology City Hospital Nottingham
  Nottingham City Hospital
  Hucknall Road
  Nottingham
  NG5 1PB
  UK
• work0115 82 31850
• fax0115 82 31849
• poulam.patel@nottingham.ac.uk

Recent Publications

• MALECKA A, WANG Q, SHAH S, SUTAVANI R, SPENDLOVE I, RAMAGE J, GREENSMITH J, FRANKS H, GOUGH MJ, SAALBACH A, PATEL PM and JACKSON AM, 2016. Stromal fibroblasts support dendritic cells to maintain IL-23/Th17 responses after exposure to ionizing radiation. Journal of leukocyte biology. 100(2), 381-389
• NSENGIMANA J, LAYE J, FILIA A, WALKER C, JEWELL R, VAN DEN OORD JJ, WOLTER P, PATEL P, SUCKER A, SCHADENDORF D, JÖNSSON GB, BISHOP DT and NEWTON-BISHOP J, 2015. Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohort. Oncotarget. 6(13), 11683-93
• ABBOTTS R, JEWELL R, NSENGIMANA J, MALONEY DJ, SIMEONOV A, SEEDHOUSE C, ELLIOTT F, LAYE J, WALKER C, JADHAV A, GRABOWSKA A, BALL G, PATEL PM, NEWTON-BISHOP J, WILSON DM and MADHUSUDAN S, 2014. Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy. Oncotarget. 5(10), 3273-86
• DAVIS J, MARTIN SG, PATEL PM, GREEN AR, RAKHA EA, ELLIS IO and STORR SJ, 2014. Low calpain-9 is associated with adverse disease-specific survival following endocrine therapy in breast cancer. BMC cancer. 14(1), 995-1003

• View all publications

• MALECKA A, WANG Q, SHAH S, SUTAVANI R, SPENDLOVE I, RAMAGE J, GREENSMITH J, FRANKS H, GOUGH MJ, SAALBACH A, PATEL PM and JACKSON AM, 2016. Stromal fibroblasts support dendritic cells to maintain IL-23/Th17 responses after exposure to ionizing radiation. Journal of leukocyte biology. 100(2), 381-389
• NSENGIMANA J, LAYE J, FILIA A, WALKER C, JEWELL R, VAN DEN OORD JJ, WOLTER P, PATEL P, SUCKER A, SCHADENDORF D, JÖNSSON GB, BISHOP DT and NEWTON-BISHOP J, 2015. Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohort. Oncotarget. 6(13), 11683-93
• ABBOTTS R, JEWELL R, NSENGIMANA J, MALONEY DJ, SIMEONOV A, SEEDHOUSE C, ELLIOTT F, LAYE J, WALKER C, JADHAV A, GRABOWSKA A, BALL G, PATEL PM, NEWTON-BISHOP J, WILSON DM and MADHUSUDAN S, 2014. Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy. Oncotarget. 5(10), 3273-86
• DAVIS J, MARTIN SG, PATEL PM, GREEN AR, RAKHA EA, ELLIS IO and STORR SJ, 2014. Low calpain-9 is associated with adverse disease-specific survival following endocrine therapy in breast cancer. BMC cancer. 14(1), 995-1003
• BOGAERTS J, SYDES MR, KEAT N, MCCONNELL A, BENSON A, HO A, ROTH A, FORTPIED C, ENG C, PECKITT C, COENS C, PETTAWAY C, ARNOLD D, HALL E, MARSHALL E, SCLAFANI F, HATCHER H, EARL H, RAY-COQUARD I, PAUL J, BLAY JY, WHELAN J, PANAGEAS K, WHEATLEY K, HARRINGTON K, LICITRA L, BILLINGHAM L, HENSLEY M, MCCABE M, PATEL PM, CARVAJAL R, WILSON R, GLYNNE-JONES R, MCWILLIAMS R, LEYVRAZ S, RAO S, NICHOLSON S, FILIACI V, NEGROUK A, LACOMBE D, DUPONT E, PAUPORTÉ I, WELCH JJ, LAW K, TRIMBLE T and SEYMOUR M, 2014. Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. European journal of cancer (Oxford, England : 1990). 51(3), 271-81
• MOTZER RJ, BARRIOS CH, KIM TM, FALCON S, COSGRIFF T, HARKER WG, SRIMUNINNIMIT V, PITTMAN K, SABBATINI R, RHA SY, FLAIG TW, PAGE R, BAVBEK S, BECK JT, PATEL P, CHEUNG FY, YADAV S, SCHIFF EM, WANG X, NIOLAT J, SELLAMI D, ANAK O and KNOX JJ, 2014. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 32(25), 2765-72
• FLAHERTY KT, HENNIG M, LEE SJ, ASCIERTO PA, DUMMER R, EGGERMONT AM, HAUSCHILD A, KEFFORD R, KIRKWOOD JM, LONG GV, LORIGAN P, MACKENSEN A, MCARTHUR G, O'DAY S, PATEL PM, ROBERT C and SCHADENDORF D, 2014. Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. The Lancet. Oncology. 15(3), 297-304
• DAVIES JR, JEWELL R, AFFLECK P, ANIC GM, RANDERSON-MOOR J, OZOLA A, EGAN KM, ELLIOTT F, GARCÍA-CASADO Z, HANSSON J, HARLAND M, HÖIOM V, JIAN G, JÖNSSON G, KUMAR R, NAGORE E, WENDT J, OLSSON H, PARK JY, PATEL P, PJANOVA D, PUIG S, SCHADENDORF D, SIVARAMAKRISHNA RACHAKONDA P, SNOWDEN H, STRATIGOS AJ, BAFALOUKOS D, OGBAH Z, SUCKER A, VAN DEN OORD JJ, VAN DOORN R, WALKER C, OKAMOTO I, WOLTER P, BARRETT JH, TIMOTHY BISHOP D and NEWTON-BISHOP J, 2014. Inherited variation in the PARP1 gene and survival from melanoma. International journal of cancer. 135(7), 1625-33
• LUKE JJ, TRIOZZI PL, MCKENNA KC, VAN MEIR EG, GERSHENWALD JE, BASTIAN BC, GUTKIND JS, BOWCOCK AM, STREICHER HZ, PATEL PM, SATO T, SOSSMAN JA, SZNOL M, WELCH J, THURIN M, SELIG S, FLAHERTY KT and CARVAJAL RD, 2014. Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment cell & melanoma research. 28(2), 135-47
• EGGERMONT AM, SUCIU S, RUTKOWSKI P, MARSDEN J, SANTINAMI M, CORRIE P, AAMDAL S, ASCIERTO PA, PATEL PM, KRUIT WH, BASTHOLT L, BORGOGNONI L, BERNENGO MG, DAVIDSON N, POLDERS L, PRAET M and SPATZ A, 2013. Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(30), 3831-7
• WANG, Q., FRANKS, H.A., LAX, S.J., EL REFAEE, M., MALECKA, A., SHAH, S., SPENDLOVE, I., GOUGH, M.J., SEEDHOUSE, C., MADHUSUDAN, S., PATEL, P.M. and JACKSON, A.M., 2013. The ataxia telangiectasia mutated kinase pathway regulates IL-23 expression by human dendritic cells Journal of Immunology. 190(7), 3246-3255
• STORR SJ, SAFUAN S, MITRA A, ELLIOTT F, WALKER C, VASKO MJ, HO B, COOK M, MOHAMMED RA, PATEL PM, ELLIS IO, NEWTON-BISHOP JA and MARTIN SG, 2012. Objective Assessment Of Blood And Lymphatic Vessel Invasion And Association With Macrophage Infiltration In Cutaneous Melanoma. Modern Pathology : An Official Journal Of The United States And Canadian Academy Of Pathology, Inc. 25(4), 493-504
• SULTANA, R., MCNEILL, D.R., ABBOTTS, R., MOHAMMED, M.Z., ZDZIENICKA, M.Z., QUTOB, H., SEEDHOUSE, C., LAUGHTON, C.A., FISCHER, P.M., PATEL, P.M., WILSON, D.M. and MADHUSUDAN, S., 2012. Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors International Journal of Cancer. 131(10), 2433-2444
• SAFUAN S, STORR SJ, PATEL PM and MARTIN SG, 2012. A comparative study of adhesion of melanoma and breast cancer cells to blood and lymphatic endothelium. Lymphatic research and biology. 10(4), 173-81
• EGGERMONT AMM, SUCIU S, TESTORI A, SANTINAMI M, KRUIT WHJ, MARSDEN J, PUNT CJA, SALÈS F, DUMMER R, ROBERT C, SCHADENDORF D, PATEL PM, DE SCHAETZEN G, SPATZ A and KEILHOLZ U, 2012. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(31), 3810-8
• FRANKS HA, WANG Q and PATEL PM, 2012. New anticancer immunotherapies. Anticancer research. 32(7), 2439-53
• EGGERMONT AMM, SUCIU S, TESTORI A, KRUIT WH, MARSDEN J, PUNT CJ, SANTINAMI M, SALÈS F, SCHADENDORF D, PATEL P, DUMMER R, ROBERT C, KEILHOLZ U, YVER A and SPATZ A, 2012. Ulceration And Stage Are Predictive Of Interferon Efficacy In Melanoma: Results Of The Phase Iii Adjuvant Trials Eortc 18952 And Eortc 18991. European Journal Of Cancer (Oxford, England : 1990). 48(2), 218-25
• WANG, Q., FRANKS, H.A., PORTE, J., EL REFAAE, M., SHAH, S., CROOKS, J., PATEL, P.M. and JACKSON, A.M., 2011. Novel approach for interleukin-23 up-regulation in human dendritic cells and the impact on T helper type 17 generation Immunology. 134(1), 60-72
• PATEL PM, SUCIU S, MORTIER L, KRUIT WH, ROBERT C, SCHADENDORF D, TREFZER U, PUNT CJA, DUMMER R, DAVIDSON N, BECKER J, CONRY R, THOMPSON JA, HWU W, ENGELEN K, AGARWALA SS, KEILHOLZ U, EGGERMONT AMM, SPATZ A and EORTC MELANOMA GROUP, 2011. Extended Schedule, Escalated Dose Temozolomide Versus Dacarbazine In Stage Iv Melanoma: Final Results Of A Randomised Phase Iii Study (Eortc 18032). European Journal Of Cancer (Oxford, England : 1990). 47(10), 1476-83
• BOUWHUIS MG, SUCIU S, KRUIT W, SALÈS F, STOITCHKOV K, PATEL P, COCQUYT V, THOMAS J, LIÉNARD D, EGGERMONT AMM, GHANEM G and EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER MELANOMA GROUP, 2011. Prognostic Value Of Serial Blood S100b Determinations In Stage Iib-Iii Melanoma Patients: A Corollary Study To Eortc Trial 18952. European Journal Of Cancer (Oxford, England : 1990). 47(3), 361-8
• JACKSON, AM, MULCAHY, LA, PORTE, J, FRANKS, HA, EL REFAEE, M, WANG, Q, SHAH, S, ZHU, X and PATEL, PM, 2010. Role of mitogen-activated protein kinase and PI3K pathways in the regulation of IL-12-family cytokines in dendritic cells and the generation of TH-responses European Cytokine Network. 21(4), 319-328
• ALEXANDROFF AB, NICHOLSON S, PATEL PM and JACKSON AM, 2010. Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer. Immunotherapy. 2(4), 551-60
• ZOLADEK A, PASCUT FC, PATEL PM, NOTINGHER I, 2010. Non-invasive time-course imaging of apoptotic cells by confocal Raman micro-spectroscopy Journal of Raman Spectroscopy.
• EL-HARIRY I, POWLES T, LAU MR, STERNBERG CN, RAVAUD A, VON DER MAASE H, ZANTL N, HARPER P, ROLLAND F, AUDHUY B, BARTHEL F, MACHIELS J, PATEL P, KREUSER E and HAWKINS RE, 2010. Amplification Of Epidermal Growth Factor Receptor Gene In Renal Cell Carcinoma. European Journal Of Cancer (Oxford, England : 1990). 46(5), 859-62
• BOUWHUIS, M.G., SUCIU, S., TESTORI, A., KRUIT, W.H., SALÈS, F., PATEL, P., PUNT, C.J., SANTINAMI, M., SPATZ, A., TEN HAGEN, T.L.M. and EGGERMONT, A.M.M., 2010. Phase III trial comparing adjuvant treatment with pegylated interferon alfa-2b versus observation: prognostic significance of autoantibodies: EORTC 18991 Journal of Clinical Oncology. 28(14), 2460-2466
• GORE, M.E., GRIFFIN, C.L., HANCOCK, B., PATEL, P.M., PYLE, L., AITCHISON, M., JAMES, N., OLIVER, R.T.D., MARDIAK, J., HUSSAIN, T., SYLVESTER, R., PARMAR, M.K.B., ROYSTON, P. and MULDERS, P.F.A., 2010. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial Lancet. 375(9715), 641-648
• BOUWHUIS, M.G., SUCIU, S., COLLETTE, S., AAMDAL, S., KRUIT, W.H., BASTHOLT, L., STIERNER, U., SALÈS, F., PATEL, P., PUNT, C.J.A., HERNBERG, M., SPATZ, A., TEN HAGEN, T.L.M., HANSSON, J. and EGGERMONT, A.M.M., 2009. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon Journal of the National Cancer Institute. 101(12), 869-877
• BOTTOMLEY, A., COENS, C., SUCIU, S., SANTINAMI, M., KRUIT, W., TESTORI, A., MARSDEN, J., PUNT, C., SALÈS, F., GORE, M., MACKIE, R., KUSIC, Z., DUMMER, R., PATEL, P., SCHADENDORF, D., SPATZ, A., KEILHOLZ, U. and EGGERMONT, A., 2009. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation For Research And Treatment Of Cancer Melanoma Group Journal Of Clinical Oncology. 27(18), 2916-2923
• WEST E, MORGAN R, SCOTT K, MERRICK A, LUBENKO A, PAWSON D, SELBY P, HATFIELD P, PRESTWICH R, FRASER S, EVES D, ANTHONEY A, TWELVES C, BEIRNE D, PATEL P, O'DONNELL D, WATT S, WALLER M, DIETZ A, ROBINSON P and MELCHER A, 2009. Clinical Grade Ok432-Activated Dendritic Cells: In Vitro Characterization And Tracking During Intralymphatic Delivery. Journal Of Immunotherapy (Hagerstown, Md. : 1997). 32(1), 66-78
• HUBER, K., PATEL, P., ZHANG, L., EVANS, H., WESTWELL, A.D., FISCHER, P.M., CHAN, S. and MARTIN, S., 2008. 2-[(1-Methylpropyl)dithio]-1H-imidazole inhibits tubulin polymerization through cysteine oxidation Molecular Cancer Therapeutics. 7(1), 143-151
• ZHU, X., MULCAHY, L.A., MOHAMMED, R.A., LEE, A.H., FRANKS, H.A., KILPATRICK, L., YILMAZER, A., PAISH, E.C., ELLIS, I.O., PATEL, P.M. and JACKSON, A.M., 2008. IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines Breast Cancer Research. 10(6), R95
• PATEL, P M, SIM, S, O'DONNELL, D O, PROTHEROE, A, BEIRNE, D, STANLEY, A, TOURANI, J M, KHAYAT, D, HANCOCK, B, VASEY, P, DALGLEISH, A, JOHNSTON, C, BANKS, R E and SELBY, P J, 2008. An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer. European Journal of Cancer. 44(2), 216-23
• VASUDEV, NAVEEN S, BROWN, JANET E, BROWN, SARAH R, RAFIQ, RUMANA, MORGAN, RUTH, PATEL, POULAM M, O'DONNELL, DEARBHAILE, HARNDEN, PATRICIA, ROGERS, MARK, COCKS, KIM, ANDERSON, KIRSTY, PAUL, ALAN and EARDL, 2008. Prognostic factors in renal cell carcinoma: association of preoperative sodium concentration with survival. Clinical Cancer Research. 14(6), 1775-81
• JACKSON, A.M., MULCAHY, L.A., ZHU, X.W., O'DONNELL, D. and PATEL, P.M., 2008. Tumour-mediated disruption of dendritic cell function: inhibiting the MEK1/2-p44/42 axis restores IL-12 production and Th1-generation International Journal of Cancer. 123(3), 623-632
• ROLLAND, PHIL, SPENDLOVE, IAN, MADJID, ZAHRA, RAKHA, EMAD A, PATEL, POULAM, ELLIS, IAN O and DURRANT, LINDY, 2007. The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer. International Journal of Cancer. 120(6), 1311-7
• SCHMIDT, H., SUCIU, S., PUNT, C.J., GORE, M., KRUIT, W., PATEL, P., LIENARD, D., VON DER MAASE, H., EGGERMONT, A.M., KEILHOLZ, U., AMERICAN JOINT COMMITTEE ON CANCER STAGE IV MELANOMA and EORTC 18951., 2007. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol. 25(12), 1562-9
• SHAW DM, CONNOLLY NB, PATEL PM, KILANY S, HEDLUND G, NORDLE O, FORSBERG G, ZWEIT J, STERN PL, HAWKINS RE., 2007. A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer.. 96(4), 567-574
• LARKIN, J M G, HUGHES, S A, BEIRNE, D A, PATEL, P M, GIBBENS, I M, BATE, S C, THOMAS, K, EISEN, T G and GORE, M E, 2007. A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. British Journal of Cancer. 96(1), 44-8
• LEE, C.P., PATEL, P.M., SELBY, P.J., HANCOCK, B.W., MAK, I., PYLE, L., JAMES, M.G., BEIRNE, D.A., STEEDS, S., A'HERN, R., GORE, M.E. and EISEN, T., 2006. Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology. 24(6), 898-903
• WATSON, N.F., DURRANT, L.G., SCHOLEFIELD, J.H., MADJD, Z., SCRIMGEOUR, D., SPENDLOVE, I., ELLIS, I.O. and PATEL, P.M., 2006. Cytoplasmic expression of p27(kip1) is associated with a favourable prognosis in colorectal cancer patients World Journal of Gastroenterology. 12(39), 6299-6304
• KRUIT, W. H. J., VAN OJIK, H. H., BRICHARD, V. G., ESCUDIER, B., DORVAL, T., DRENO, B., PATEL, P., VAN BAREN, N., AVRIL, M.-F. and PIPERNO, S., 2005. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma International Journal of Cancer. VOL 117(NUMB 4), 596-604
• VASUDEV,N. and PATEL,P.M., 2005. Renal Cancer. In: EARDLEY, I., WHELAN, P., KIRBY, R. and SCHAEFFER, A., eds., Drug Treatment in Urology Blackwell Publishing.
• FERGUSON, R. E., JACKSON, S. M., STANLEY, A. J., JOYCE, A. D., HARNDEN, P., MORRISON, E. E., PATEL, P. M., PHILLIPS, R. M., SELBY, P. J. and BANKS, R. E., 2005. Intrinsic chemotherapy resistance to the tubulin-binding antimitotic agents in renal cell carcinoma International Journal of Cancer. VOL 115(NUMB 1), 155-163
• FERGUSON, R. E., TAYLOR, C., STANLEY, A., BUTLER, E., JOYCE, A., HARNDEN, P., PATEL, P. M., SELBY, P. J. and BANKS, R. E., 2005. Resistance to the Tubulin-Binding Agents in Renal Cell Carcinoma: No Mutations in the Class I beta-Tubulin Gene but Changes in Tubulin Isotype Protein Expression Clinical Cancer Research. VOL 11(NUMB 9), 3439-3445
• KEILHOLZ, U., PUNT, C. J. A., GORE, M., KRUIT, W., PATEL, P., LIENARD, D., THOMAS, J., PROEBSTLE, T. M., SCHMITTEL, A. and SCHADENDORF, D., 2005. Dacarbazine, Cisplatin, and Interferon-Alfa-2b With or Without Interleukin-2 in Metastatic Melanoma: A Randomized Phase III Trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group Journal of Clinical Oncology. VOL 23(NUMB 27), 6747-6755
• MEARS, R., CRAVEN, R. A., HANRAHAN, S., TOTTY, N., UPTON, C., YOUNG, S. L., PATEL, P., SELBY, P. J. and BANKS, R. E., 2004. Proteomic analysis of melanoma-derived exosomes by two-dimensional polyacrylamide gel electrophoresis and mass spectrometry Proteomics. VOL 4(NUMB 12), 4019-4031
• PONCHEL,F., VERBURG,R.J., BINGHAM,S.J., BROWN,A.K., MOORE,J., PROTHEROE,A., SHORT,K., LAWSON,C.A., MORGAN,A.W., QUINN,M., BUCH,M., FIELD,S.L., MALTBY,S.L., MASUREL,A., DOUGLAS,S.H., STRASZYNSKI,L., FEARON,U., VEALE,D.J., PATEL,P., MCGONAGLE,D., SNOWDEN,J., MARKHAM,A.F., MA,D., VANLAAR,J.M., PAPADAKI,H.A., EMERY,P. and ISAACS,J.D, 2004. Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia. Arthritis Research & Therapy. 7(1), R80-R92
• CRAVEN, R. A., STANLEY, A. J., HANRAHAN, S., TOTTY, N., JACKSON, D. P., POPESCU, R., TAYLOR, A., FREY, J., SELBY, P. J. and PATEL, P. M. AND BANKS, R.E., 2004. Identification of proteins regulated by interferon-alpha in resistant and sensitive malignant melanoma cell lines Proteomics. VOL 4(NUMB 12), 3998-4009
• YOUNG, SL, MURPHY, M, ZHU, XW, HARNDEN, P, O'DONNELL, MA, JAMES, K, PATEL, PM, SELBY, PJ and JACKSON, AM, 2004. Cytokine-modified Mycobacterium smegmatis as a novel anticancer immunotherapy. International Journal of Cancer. 112(4), 653-660
• JACKSON, D.P., WATLING, D., ROGERS, N.C., BANKS, R.E., KERR, I.M., SELBY, P.J. and PATEL, P.M., 2003. The JAK/STAT pathway is not sufficient to sustain the antiproliferative response in an interferon-resistant human melanoma cell line Melanoma Research. 13(3), 219-230
• POPESCU,R.A., PATEL,P.M. and SPENCER,J., 2002. Imaging and Investigation of Melanoma Patients.. In: BISHOP, J.N. and GORE, M, eds., Melanoma: Critical Debates Blackwell Scientific Publications Ltd, Oxford, London, Edinburgh, Boston, Melbourne. 133-149
• BANKS, R.E., PATEL, P.M., STANLEY, A.J., FORBES, M.A., STARK, D., HALLAM, R.W., CARTER, C.J., BOWMER, M., JONES, M., WADWHA, P., DILGER, R., THORPE, H., PARMER, H. and SELBY, P.J., 2002. Clinical and Immunobiological effects of subcutaneous recombinant human interleukin-12 in patients with metastatic renal cancer. UroOncology. 2(1), 1-13
• SMITH, SG, PATEL, PM, SELBY, PJ and JACKSON, AM, 2001. The response of human dendritic cells to recombinant adenovirus, recombinant Mycobacterium bovis Bacillus Calmette Guerin and biolistic methods of antigen delivery: different induction of contact-dependant and soluble signals Immunology Letters. VOL 76(NUMBER 2), 79 - 88
• STANLEY, A.J., GOUGH, M.J., BANKS, R.E., SELBY, P.J. and PATEL, P.M., 2001. Renal carcinoma cell lines inhibit natural killer activity via the CD94 receptor molecule Cancer Immunology, Immunotherapy. 50(5), 260-268